CIK 0001650664 · Non-accelerated filer<br>Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464097528
- Phone
- 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,092
- in 3 filings, $19K under 10b5-1 plans
Net −$19,092. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-05 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award | +16,533 | 78,193 | ||
| 2026-11-05 | O'Neill Gilmore Neil CEO | Grant or award | +43,567 | 286,756 | ||
| 2026-09-08 | Ory Daniel Scott EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +950,000 | 950,000 | ||
| 2026-09-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −453 | $3.04 | $1K | 13,839 |
| 2026-09-03 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −709 | $3.04 | $2K | 61,660 |
| 2026-09-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −5,124 | $3.04 | $16K | 243,189 |
| 2026-08-06 | Ellinor Patrick Thomas II Director | Grant or award · Stock Option (right to buy) | +103,400 | 103,400 | ||
| 2026-08-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −678 | $2.58 | $2K | 14,292 |
| 2026-07-28 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −4,928 | $2.67 | $13K | 62,369 |
| 2026-06-17 | Connaughton Bernadette Director | Grant or award · Stock Option (right to buy) | +51,700 | 51,700 | ||
| 2026-06-17 | Hopfield Jessica Director | Grant or award · Stock Option (right to buy) | +51,700 | 51,700 | ||
| 2026-06-17 | Hirsch Andrew Director | Grant or award · Stock Option (right to buy) | +51,700 | 51,700 | ||
| 2026-06-17 | Scadden David Director | Grant or award · Stock Option (right to buy) | +51,700 | 51,700 | ||
| 2026-06-17 | Levy Elliott M. Director | Grant or award · Stock Option (right to buy) | +51,700 | 51,700 | ||
| 2026-06-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −464 | $2.70 | $1K | 14,970 |
| 2026-06-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −15,380 | $2.70 | $42K | 248,313 |
| 2026-06-03 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −731 | $2.70 | $2K | 67,297 |
| 2026-03-12 | O'Neill Gilmore Neil CEO | Grant or award · Stock Option (right to buy) 10b5-1 | +1,015,200 | 1,015,200 | ||
| 2026-03-12 | Parison Amy SVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) 10b5-1 | +292,856 | 292,856 | ||
| 2026-03-12 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) 10b5-1 | +292,856 | 292,856 |
Page 1 of 15 · 283 trades